- The acquisition will strengthen GSK’s respiratory diseases portfolio, currently buoyed by its strong launch of the respiratory syncytial virus (RSV) vaccine.
- Established in 2023, Aiolos is in the process of developing a breakthrough drug for grown-up asthma patients, already poised to enter advanced stage trials.
GSK’s ability to combat respiratory diseases will be greatly bolstered by this acquisition, primarily riding on the surge triggered by the successful roll-out of its respiratory syncytial virus (RSV) vaccine.
Aiolos, birthed in 2023, is currently spearheading the development of a promising therapeutic solution for adults grappling with asthma. The medication is all set to enter the critical phase of late-stage trials.
Given the medical importance of both GSK and Aiolos, this acquisition could impact forex trading, possibly influencing the values of healthcare-sector assets.